COMPANY RESEARCHInternational full-service CRO with China delivery and published early-phase partner-site information. Confirm the actual team, indication and protocol rather than assuming global coverage establishes IIT fit.
Profile review: 2026-11-06 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
International full-service CRO with China delivery and published early-phase partner-site information. Confirm the actual team, indication and protocol rather than assuming global coverage establishes IIT fit.
International delivery scope: International CRO with China operations
IIT evidence: IIT capability not established by reviewed sources
Individual program detail is not recorded. Consult the original sources below.
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
CSPC announced initiation of the first Chinese center for SYS6055-003, a Phase 1/2 trial in relapsed or refractory B-cell non-Hodgkin lymphoma. SYS6055 uses lentiviral vectors to generate CD19-targeting CAR-T cells in vivo. The company said recruitment and screening are underway following October clinical-trial authorization. Center initiation does not establish patient dosing, efficacy, or marketing approval.
The China National Center for Biotechnology Development published its fifteenth batch of biomedical clinical research filings on November 4. Seven projects completed filing between October 27 and November 4. The notice emphasizes institutional responsibility, internal quality management, training, data traceability, and participant protection. Filing concerns the research pathway; it is not evidence of therapeutic efficacy or product marketing authorization.
Historical methods study (2017): 213 sites from 11 academic trials were randomised; audits covered 156 sites and 1,618 patients. Risk-adapted monitoring met the specified non-inferiority criterion for major audit findings while using fewer resources. High-risk trials were excluded. The findings inform monitoring design, not the performance of any Chinese CRO.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.